医学临床研究
  2025年4月3日 星期四           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (9): 1392-1394    DOI: 10.3969/j.issn.1671-7171.2024.09.031
  论著 本期目录 | 过刊浏览 | 高级检索 |
神经节苷脂联合左乙拉西坦治疗儿童病毒性脑炎继发癫痫的有效性及安全性分析
李传萍, 李华丽
西华县人民医院,河南 周口 466600
Efficacy and Safety Analysis of Ganglioside Combined with Levetiracetam in the Treatment of Secondary Epilepsy in Children with Viral Encephalitis
LI Chuanping, LI Huali
Xihua County People's Hospital,Zhoukou Henan 466600
全文: PDF (1190 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨神经节苷脂联合左乙拉西坦治疗儿童病毒性脑炎继发癫痫的有效性及安全性。【方法】选取2021年1月至2023年1月本院收治的71例病毒性脑炎继发癫痫患儿,根据治疗方法不同将其分为对照组(n=35,常规治疗+左乙拉西坦)和观察组(n=36,在对照组治疗的基础上联合神经节苷脂)。比较两组的临床疗效、血清指标[神经元特异性烯醇化酶(NSE)、白细胞介素6(IL-6)、肿瘤坏死因子(TNF-α)]、脑脊液指标[肺表面活性物质相关蛋白D(SP-D)、半乳糖凝集素-9(Gal-9)],以及治疗后癫痫发作频率、安全性。【结果】治疗后,观察组临床有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清NSE、IL-6、TNF-α水平及脑脊液Gal-9水平低于治疗前,且观察组低于对照组(P<0.05);两组脑脊液SP-D水平高于治疗前,且观察组高于对照组(P<0.05)。出院后,观察组癫痫未发作或发作频率减少情况优于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】神经节苷脂联合左乙拉西坦治疗病毒性脑炎继发癫痫患儿的临床效果较好,可改善患儿免疫反应,有效降低患儿癫痫发作频率,安全性较好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
李传萍
李华丽
关键词 脑炎,病毒性癫痫神经节苷脂类/治疗应用左乙拉西坦/治疗应用治疗结果    
Abstract:【Objective】To investigate the efficacy and safety of ganglioside combined with levetiracetam in the treatment of secondary epilepsy in children with viral encephalitis. 【Methods】A total of 71 children with secondary epilepsy caused by viral encephalitis admitted to our hospital from January 2021 to January 2023 were selected. According to the treatment method, they were divided into the control group (n=35, conventional treatment + levetiracetam) and the observation group (n=36, combined with ganglioside on the basis of treatment in the control group). The clinical efficacy, serum indicators [neuron specific enolase (NSE), serum interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α)], cerebrospinal fluid indicators [pulmonary surfactant protein D (SP-D), galectin-9 (Gal-9)], as well as the frequency and safety of epileptic seizures after treatment were compared between two groups of children. 【Result】After treatment, the clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of serum NSE, IL-6, TNF-α, and cerebrospinal fluid Gal-9 in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05); The levels of SP-D in the cerebrospinal fluid of both groups were higher than before treatment, and the observation group was higher than the control group (P<0.05). After discharge, the observation group showed better results than the control group in terms of no seizures or reduced seizure frequency (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The clinical effect of ganglioside combined with levetiracetam in the treatment of secondary epilepsy in children with viral encephalitis is good, improving their immune response, effectively reducing the frequency of seizures, and ensuring good safety.
Key wordsEncephalitis, Viral    Epilepsy    Gangliosides/TU    Levetiracetam/TU    Treatment Outcome
收稿日期: 2023-10-14     
中图分类号:  R725.123  
引用本文:   
李传萍, 李华丽. 神经节苷脂联合左乙拉西坦治疗儿童病毒性脑炎继发癫痫的有效性及安全性分析[J]. 医学临床研究, 2024, 41(9): 1392-1394.
LI Chuanping, LI Huali. Efficacy and Safety Analysis of Ganglioside Combined with Levetiracetam in the Treatment of Secondary Epilepsy in Children with Viral Encephalitis. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1392-1394.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.09.031     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I9/1392
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn